An observational study in Nocturia, sponsored by Ferring Pharmaceuticals. Completed at 83 sites in Czech Republic. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2014-01-06.
Sponsored by Ferring Pharmaceuticals · Observational
This is a confirmation of safety profile for Minirin Melt in clinical practice.
124 studies on the registry are indexed under Nocturia; 24 are open to participants now.
This study's enrollment of 2,187 is above the median of 275 across 24 observational studies indexed under Nocturia.
Browse Nocturia studies →Ferring Pharmaceuticals is the lead sponsor of 244 studies on the registry; 4 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 13 (93%) have results posted.
Counted across the registry records on this site, refreshed daily.
primary care clinic
Exclusion Criteria:
Verify the safety profile
Time frame: 12 months
Safety aspect of dosage
Time frame: 12 months
This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ferring Pharmaceuticals